10:53:06 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.

Kalender

2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020
2021-05-19 16:55:54
OSLO/LONDON, May 19th 2021: EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company"),
a clinical stage precision medicine company utilizing Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announced that it has been
granted a patent for its innovative Acoustic Cluster Therapy® technology in
Japan.

The patent covers EXACT-Tx`s unique microbubble/microdroplet formulation and its
use, co-administered with a range of pharmaceutical agents for ultrasound
mediated therapeutic targeting.

"We are delighted with the decision of the Japanese Patent Office in granting
this important patent for ACT®, which complements the existing patent granted in
China in November 2019. This core patent represents the foundation of our
dynamic IP strategy, which encompasses the use of ACT® with a variety of
therapeutics across a multitude of indications", said Dr Rafiq Hasan, CEO of
EXACT Therapeutics AS.

About ACT®

o ACT® comprises a proprietary formulation consisting of microbubbles and
microdroplets that is activated through the application of ultrasound with the
consequent increase in targeted delivery of a co-administered therapeutic agent.

o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however, the ACT® platform has
potential across multiple therapeutic areas (infectious diseases, CNS,
immunotherapy) and classes of therapeutic agents.

About EXACT-Tx

EXACT-Tx is a clinical stage Norwegian biopharmaceutical company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated,
targeted drug enhancement - with the potential to significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy), infectious
diseases, and neurological conditions. www.exact-tx.com



For more information contact:

Dr Rafiq Hasan, CEO EXACT Therapeutics
Rafiq@exact-tx.com